THE ECONOMIC BURDEN OF METASTATIC NON-SMALL CELL LUNG CANCER IN US PATIENTS WITHOUT AN EGFR OR ALK MUTATION

被引：0
|
作者：
Simmons, D. [1 ]
Welch, E. [2 ]
Pyrih, N. [3 ]
Jiang, Z. [1 ]
Xiao, Y. [1 ]
Jassim, R. [1 ]
机构：
[1] AstraZeneca, Gaithersburg, MD USA
[2] Panalgo, Boston, MA USA
[3] Cobbs Creek Healthcare, Concordville, MD USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE270
引用
收藏
页码：S108 / S108
页数：1
相关论文
共 50 条
  • [31] ERBB2 alteration with or without co-existent EGFR mutation in metastatic non-small cell lung cancer
    Singh, Vijendra
    Baca, Yasmine
    Kim, Seongho
    Boumber, Yanis
    Mamdani, Hirva
    Kim, Edward S.
    Sukari, Ammar
    Kim, Chul
    Bepler, Gerold
    Liu, Stephen, V
    Spira, Alexander, I
    Borghai, Hossein
    Nagasaka, Mikaso
    CANCER RESEARCH, 2020, 80 (16)
  • [32] Impact of EGFR mutation analysis in non-small cell lung cancer
    Yamamoto, Hiromasa
    Toyooka, Shinichi
    Mitsudomi, Tetsuya
    LUNG CANCER, 2009, 63 (03) : 315 - 321
  • [33] Concomitant EGFR Mutation and ALK Rearrangement in Non-Small-Cell Lung Cancer
    Chen, R.
    Zhang, X.
    Wu, Y.
    Chen, H.
    Zhou, Q.
    Su, J.
    Tu, H.
    Xie, Z.
    Zhong, W.
    Yang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2225 - S2226
  • [34] FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Kazandjian, Dickran
    Blumenthal, Gideon M.
    Yuan, Weishi
    He, Kun
    Keegan, Patricia
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2016, 22 (06) : 1307 - 1312
  • [35] TREATMENT LANDSCAPE AND KEY DRIVERS FOR HTA DECISIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITHOUT EGFR OR ALK ALTERATIONS
    Henry, A.
    Hollier-Hann, G.
    Ralston, S.
    VALUE IN HEALTH, 2019, 22 : S507 - S507
  • [36] Circulating tumor cells and evaluation of targeted therapy effect in EGFR mutation/ALK translocation metastatic non-small cell lung cancer.
    Su, ChunXia
    Li, Xuefei
    Ren, Shengxiang
    Gao, Guanghui
    Li, Wei
    Zhao, Jing
    Chen, Xiaoxia
    Zhao, Chao
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] EGFR Mutation in Non-Small Cell Lung Cancer is Influenced by EGFR Amplification and Biomarkers
    Pollen, M.
    Waterman, J. P.
    Ding, M.
    Alvarez, A.
    Boyd, M.
    Streifel, J.
    Noroberg, M. L.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2009, 11 (06): : 655 - 655
  • [38] Economic burden in patients with ALK plus non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors
    Lin, Huamao M.
    Pan, Xiaoyun
    Hou, Peijie
    Huang, Hui
    Wu, Yanyu
    Ren, Kaili
    Jahanzeb, Mohammad
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (08) : 894 - 901
  • [39] Brain metastases in patients with ALK plus non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden
    Guerin, Annie
    Sasane, Medha
    Zhang, Jie
    Culver, Kenneth W.
    Dea, Katherine
    Nitulescu, Roy
    Wu, Eric Qiong
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (04) : 312 - 322
  • [40] EGFR/ALK Mutations in Stage III Non-small Cell Lung Cancer Patients Received Chemoradiotherapy
    Nyaw, S. F.
    Tin, W. Y.
    Lo, S. H.
    Tung, Y.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S759 - S760
12345